New Discovered Makers for Depression in SLE

For decades, scientists, and clinicians have known that systemic lupus erythematosus (SLE), has a complex origin involving genetics, hormones, and environmental influences. Lupus posed major challenges for patients and physicians because treatment options are often only partially effective and can carry major side effects.

One of the most common neuropsychiatric complications of lupus is major depressive disorder in SLE (SLEMDD). This refers to clinical depression occurring in patients with lupus, often involving persistent sadness, fatigue, loss of interest, sleep disturbance, difficulty concentrating, and feelings of hopelessness. Increasing evidence suggests that, in many patients, depression may arise both from biological immune and inflammatory mechanisms directly related to lupus itself, meaning SLEMDD may need treatment beyond standard psychiatric care. A 2026 study titled An immunometabolic signature of major depressive disorder in systemic lupus erythematosus gives new insights into this problem.

*Disclaimer:

The information provided in this article is for general informational purposes only and is not intended as medical advice. It should not be used as a substitute for professional diagnosis, treatment, or advice from a qualified healthcare provider. Reliance on any information provided in this article is solely at your own risk.

See a word you don't understand? Find it in our glossary.

The researchers wanted to identify candidate biomarkers associated with depression in lupus. Specifically, they wanted to determine whether patients with SLEMDD have measurable differences in:

• Immune cell populations

• Gut microbiota composition

• Metabolic pathways and circulating metabolites

Essentially, they were looking for a biological “signature” that could distinguish lupus patients with depression from those without depression.

This research would be clinically valuable because biomarkers could help researchers:

• Diagnose neuropsychiatric lupus earlier

• Personalize treatment strategies

• Monitor response to therapy

• Better understand the mechanisms linking immunity and mood disorders

The study analyzed 99 patients with SLE from the LUPIL-2 cohort. Researchers used many techniques:

• Immune phenotyping: Blood samples were studied to measure immune cell subsets, especially T cells and regulatory T cells

• Gut microbiota profiling: Stool samples were analyzed for bacterial diversity and specific microbial species.

• Metabolomics: Blood metabolites were measured, focusing on pathways such as kynurenine metabolism and short-chain fatty acids like butyrate.

• Statistical modeling: Researchers used data analysis tools to identify patterns and predict which patients had SLEMDD.

• Validation: Findings were tested in an independent patient group, strengthening reliability.

The study found that lupus patients with depression had a distinct profile compared to lupus patients without depression.

• Reduced naïve CD4⁺ T cells

• Reduced naïve regulatory T cells

• Increased ICOS⁺ effector memory​

These immune differences classified SLEMDD patients with high accuracy, showing strong biomarker potential.

• Reduced overall microbial diversity

• Lower levels of Akkermansia muciniphila, a bacterium linked to gut barrier health

• Increased Faecalibacterium prausnitzii, possibly as a compensatory response​

These findings support the idea of a gut-brain-immune connection in lupus depression.

• Kynurenine pathway disruption: may reduce serotonin availability and increase inflammatory metabolites

• Lower butyrate levels: may worsen inflammation, weaken gut barrier integrity, and affect mood regulation

When immune, microbiome, and metabolic data were combined, researchers could distinguish depressed from non-depressed lupus patients with strong accuracy. This suggests depression in lupus may result from interacting immune, gut, and metabolic disturbances rather than one single cause.

This study is important because it moves lupus depression beyond the idea of being “just psychological.” It supports the view that depression in some lupus patients may reflect biological disease activity.

However, the findings should still be interpreted carefully, as the sample size was moderate (99 patients), association does not prove causation, there are more factors to depression, and larger long-term studies are needed.

However, as research continues, these biomarkers may help transform how clinicians diagnose and treat SLEMDD.

An immunometabolic signature of major depressive disorder in systemic lupus erythematosus | NIH

Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial | NIH

Major depressive disorder and disease activity in systemic lupus erythematosus | Science Direct